Bispecific anti-Erb-B antibodies and their use in tumor therapy

Details Bispecific anti-Erb-B antibodies and their use in tumor therapy Bispecific anti-Erb-B antibodies and their use in tumor therapy

2007-06-05

2007-06-05

Foley, Shanon (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S143100

Reexamination Certificate

active

10530875

ABSTRACT:
The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are overexpressed on many cancer tissues. Since the different specificities of the antigen-binding sites are directed to different epitopes within the binding domain of same or different ErbB receptors, these antibodies are more effective with respect to inhibition and down-regulation of the ErbB receptor and the corresponding signaling cascade.

REFERENCES:
patent: 5587458 (1996-12-01), King et al.
patent: 2002/0103345 (2002-08-01), Zhu
patent: WO 9400136 (1994-01-01), None
patent: WO 02055106 (2002-07-01), None
Fan et al (Cancer Research, 1993, 53:4322-4328).
Robert et al (Int J Cancer, 1999, 81:285-291).
Albanell et al (Drugs Today, 1999, 35:931-946).
Kim et al (Experimental Cell Research, 1999, 253:78-87).
Stratagene Catalog 1988, p. 39.
“ATCC:Cell Biology Collection”, p. 1-2.
ImClone, “ERBITUX”, p. 1-2.
Ye D et al.: “Augmentation of a Humanized Anti-HER2 MAB 4D5 Induced Growth Inhibition by a Human-Mouse Chimeric Anti-EGF Receptor MAB C225” Oncogene, Basingstoke, Hants, GB, vol. 18, No. 3, Jan. 21, 1999 731-738, XP001096335.
Schmidt M et al: “A Bivalent Single-Chain Antibody-Toxin Specific for ERB-2 and the EFG Receptor” International Journal of Cancer, New York, NY, US, vol. 65, No. 4, Feb. 8, 1996 pp. 538-546, XP000646380.
Kasprzyk P G et al: “Therapy of an Animal Model of Human Gastric Cancer Using a Combination of anti-ERBB-2 Monoclonal Antibodies” Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 52, May 15, 1992, pp. 2771-2776, XP001093195.
Baselga J et al: “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-P185HER2 Monoclonal Antibdy in Patients with HER2/NEU-Overexpressing Metastatic Breast Cancer” Journal of Clinical Oncology, Philadelphia, PA, US, vol. 14, No. 3, Mar. 1996 pp. 737-744, XP000918166.

Affiliated with

Also associated with

Rating

Bispecific anti-Erb-B antibodies and their use in tumor therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bispecific anti-Erb-B antibodies and their use in tumor therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific anti-Erb-B antibodies and their use in tumor therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3825501